Astrotech Corporation (ASTC) — Form 10-Q Summary
Period clarification: The filing covers the three months ended September 30, 2021, Astrotech’s fiscal first quarter of 2022—not 2020 Q1. Comparative results are for the three months ended September 30, 2020. Financial statement amounts below are in millions of dollars unless otherwise stated.
Business context
Astrotech develops and commercializes mass spectrometry technology through subsidiaries focused on security detection (1st Detect), agriculture (AgLAB), and breath analysis (BreathTech). The quarter’s revenue came from TRACER 1000 sales to DHL; one customer materially represented revenue in both comparison periods.
Financial results and liquidity
| Metric | Q1 FY2022 | Q1 FY2021 |
|---|---|---|
| Revenue | $0.187 | $0.140 |
| Gross profit / margin | $0.012 / 6% | $0.027 / 19% |
| Operating expenses | $2.065 | $2.079 |
| Operating loss | $(2.053) | $(2.052) |
| Net loss | $(2.029) | $(2.111) |
| Basic and diluted loss per share | $(0.04) | $(0.27) |
| Cash used in operations | $(2.189) | $(1.480) |
At September 30, 2021, cash and cash equivalents were $31.650 million and short-term investments were $27.302 million. Working capital was approximately $59.1 million. Total assets were $61.599 million; total liabilities were $2.110 million, including $0.500 million of related-party note payable and $0.289 million of lease liabilities. Stockholders’ equity was $59.489 million. Cash declined $4.286 million during the quarter, including $2.000 million used to repay related-party debt and interest. Capital expenditures were $0.097 million.
Changes versus the prior period
- Revenue increased $0.047 million, but cost of revenue rose $0.062 million; gross margin fell to 6% from 19%. Management cited issues with early, ultra-low-volume units and higher international shipping costs.
- SG&A increased $0.500 million to $1.426 million, mainly due to non-cash equity compensation, payroll-related accruals, and litigation expense. R&D increased $0.030 million.
- Operating cash use increased $0.709 million, partly reflecting receivables and inventory changes. Net loss improved by $0.082 million, while operating loss was essentially unchanged.
- Weighted-average common shares increased to 47.428 million from 7.719 million; loss per share is therefore not directly comparable without considering the share-count change.
Outlook, commentary, and risks
- Management said available resources should be sufficient for fiscal 2022 capital expenditure and cash-flow needs. It gave no revenue or earnings guidance and may consider capital markets, debt or equity financing, asset or technology transactions, a sale, merger, or strategic partnership.
- TRACER 1000 has ECAC certification and orders or deployments in about 20 locations across 13 countries, according to the filing. TSA cargo detection testing remained ongoing and was described as the final step toward U.S. cargo approval. 1st Detect reported a landmark purchase order for airport checkpoint deployment in August 2021.
- COVID-19 and semiconductor shortages have delayed TSA testing and disrupted parts of the supply chain. Management said prolonged shortages could hurt results, though it did not expect them to materially harm liquidity.
- Astrotech repaid the $1.0 million 2020 note and $1.0 million of principal plus accrued interest on the 2019 related-party note; the remaining $0.5 million matured September 5, 2022. The notes bore 11% interest. The CEO and board chair was the lender.
- A stockholder class and derivative action concerning a 2020 charter amendment had reached a settlement in principle; court presentation had not yet been scheduled. Separately, the Delaware Court of Chancery validated the amendment on October 6, 2021. On October 7, the company filed an amendment increasing authorized common shares from 50 million to 250 million.
- The company reported no material changes to previously disclosed risk factors, no off-balance-sheet arrangements, and effective disclosure controls. It recorded a full valuation allowance against deferred tax assets and reported no income tax benefit.
Important facts for investors to verify
- Progress and timing of final TSA cargo detection testing, approval, and any U.S. sales authorization.
- Conversion of the reported TRACER 1000 orders and deployments into revenue, and dependence on a single material customer.
- Whether production and shipping costs improve gross margin from the quarter’s 6% level.
- Cash burn, investment liquidity, and repayment of the remaining related-party note, including the associated terms and conflicts of interest.
- Status and potential costs of the stockholder litigation settlement, and implications of the increased authorized share count for possible dilution.
- Impact of supply constraints and commercialization progress for AgLAB and BreathTech; the filing does not provide quantified revenue guidance for these businesses.